Comparison of clinical effects of Rasagiline single drug and combination therapy

Rasagiline (Rasagiline) is a selective monoamine oxidase B type (MAO-B) inhibitor, mainly used for the treatment of Parkinson's disease (PD). It improves motor symptoms by inhibiting the breakdown of dopamine and prolonging the action time of dopamine between synapses. Rasagiline can be used as a single drug for patients with early-stage Parkinson's disease, or it is often used in combination with drugs such as levodopa for the middle and late stages of the disease. The specific use method depends on the patient's disease progression and individual differences.

In patients with early-stage Parkinson's disease, rasagiline monotherapy has shown good efficacy. Studies have shown that it can effectively delay the progression of motor symptoms, improve patients' quality of life, and has good tolerance and safety. Compared with other single drugs such as bromocriptine or pramipexole, rasagiline has a relatively low incidence of adverse reactions and does not cause side effects such as impulse control disorders that are common with dopamine agonists. It is suitable for older patients or patients who are intolerant to other drugs.

In patients with moderate to advanced Parkinson's disease, rasagirando is used as an auxiliary drug in combination with levodopa to reduce the "off period" and improve motor fluctuations. Multiple studies have shown that combined treatment can significantly extend the "on" time, reduce daytime symptom fluctuations, and may reduce the dose of levodopa and reduce the risk of dyskinesias induced by it. The once-daily oral regimen of rasagiline also improves patient compliance and facilitates long-term maintenance treatment.

It should be noted that in combination therapy, although rasagiline is generally well tolerated, you still need to be wary of drug-drug interactions, especially avoid using it in combination with other MAO inhibitors and certain antidepressants (such as SSRIs) to avoid inducing adverse reactions such as serotonin syndrome. In summary, rasagiline, whether used as a single agent or in combination, has shown good efficacy and safety in the treatment of Parkinson's disease, and treatment strategies should be flexibly selected based on the patient's disease progression.

Reference materials:https://www.azilect.com/